Author

Corey Ciullo

Observed institution: Intellia Therapeutics (United States)

OpenAlex ID: A5039404151

A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing

2018 · Jonathan D. Finn, Amy Rhoden Smith, et al. · Cell Reports · 898

1222 In situ CAR therapy using oRNA™ lipid nanoparticles regresses tumors in mice

2022 · Robert Mabry, Amy Becker, et al. · Journal for ImmunoTherapy of Cancer · 4

1205 Surmounting conventional cell therapy limitations via in situ CAR therapy using oRNA™ lipid nanoparticles

2023 · Amy Becker, Alex Wesselhoeft, et al. · Journal for ImmunoTherapy of Cancer · 1

Works count: 3

Citation count: 903

H-index: 2

I10-index: 1